You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
{{ message }}
Instantly share code, notes, and snippets.
Julien Hovan
JewelsHovan
I work as an AI Engineer at Compass and currently a Masters Student in Data Science, my passions include web development and web scraping.
When a change order (Trend) has assignment rows with cost impacts, those costs are attributed to packages in the CER "Package Variance" table. This works correctly at the individual package level, but group totals (Labour, Material, Equipment) over-count when a package spans multiple types.
Guide to creating a GitHub bot that teammates can @mention in issues/PRs to trigger custom workflows
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Teams Claude Agent Bot — Design Document (codebase + Confluence knowledge)
Teams Claude Agent Bot — Design Document
A Microsoft Teams bot powered by Claude Agent SDK that has deep knowledge of your codebase and Confluence documentation. Think of it as an always-available senior engineer teammate that knows the code, the docs, and the context.
What It Does
Lives in Teams as a bot you can DM or @mention in channels
Answers questions about the codebase (architecture, how things work, where things are)
Answers questions about Confluence docs (specs, decisions, runbooks, onboarding guides)
Can reason across both — e.g., "how does the auth flow described in the Auth RFC actually get implemented in the code?"
AI Avatar Influencer Tech Stack — Research Synthesis (March 2026)
AI Avatar Influencer Tech Stack — Research Synthesis
Date: March 2026 | Dimensions: 5 | Sources: 80+ | Research Method: Parallel multi-agent exploration (avatar models, video/animation, voice synthesis, case studies, startup tooling)
Executive Summary
The AI influencer space is real and monetizable — top AI personas earn $10K-$50K+/month via brand deals and Fanvue subscriptions. The tech stack has matured enough that a solo founder can launch in 48 hours using all-in-one platforms, or a small team can build a fully automated multi-persona content factory. The core insight across all research dimensions: character consistency (same face, same voice, same personality across all content) is the #1 technical challenge and the #1 differentiator between success and failure.
Databricks Vector Search — Research on incremental updates, Delta Sync vs DVAI, embeddings strategy
Databricks Vector Search — Comprehensive Research
Date: 2026-03-17
Context: We have ~7,000 chunks in a DVAI index using PubMedBERT (768-dim) embeddings with frequent incremental updates of pharmaceutical patents and FDA documents. This document consolidates research across all relevant Databricks documentation.
Topic 1: Delta Sync Index vs Direct Vector Access Index (DVAI)
Programmatic Data Lineage in Databricks Unity Catalog
Executive Summary
There are 3 approaches for programmatically getting table lineage in Databricks, each with different trade-offs. The native lineage-tracking REST API exists but is not yet in the official Python SDK. SQL system tables are the most powerful option for historical analysis.
Mitapivat (Aqvesme) — Standalone Candidate Generation Report: FDA vs USPTO Discrepancy Analysis
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
"description": "FDA reviewers questioned and effectively identified/criticized the proposed dosing/clinical regimen and primary endpoint (\u226533% reduction in transfusion burden over 24 weeks, single-arm design with dose optimization) for mitapivat prior to or contemporaneous with patent claim amendments asserting clinical methods using the compound class.",